Have a feature idea you'd love to see implemented?
Let us know!
ELTX Elicio Therapeutics Inc.
Price (delayed)
$4.78
Market cap
$51.5M
P/E Ratio
N/A
Dividend/share
N/A
EPS
-$6.83
Enterprise value
$54.1M
Highlights
Elicio Therapeutics's EPS has soared by 90% YoY and by 22% from the previous quarter
ELTX's debt is down by 13% YoY and by 3.8% QoQ
ELTX's equity has dropped by 134% since the previous quarter and by 107% year-on-year
The quick ratio has shrunk by 82% YoY and by 76% QoQ
Key stats
What are the main financial stats of ELTX
Market
Valuations
Earnings
Shares outstanding
10.77M
Market cap
$51.5M
Enterprise value
$54.1M
Price to earnings (P/E)
N/A
Price to book (P/B)
N/A
Price to sales (P/S)
N/A
EV/EBIT
N/A
EV/EBITDA
N/A
EV/Sales
N/A
Revenue
$0
EBIT
-$38.58M
EBITDA
-$37.43M
Free cash flow
-$36.21M
Per share
Balance sheet
Liquidity
EPS
-$6.83
Free cash flow per share
-$3.21
Book value per share
-$0.16
Revenue per share
$0
TBVPS
$1.4
Total assets
$15.75M
Total liabilities
$17.4M
Debt
$6.42M
Equity
-$1.65M
Working capital
-$896,000
Debt to equity
-3.89
Current ratio
0.88
Quick ratio
0.5
Net debt/EBITDA
-0.07
Margins
Efficiency
Dividend
EBITDA margin
N/A
Gross margin
N/A
Net margin
N/A
Operating margin
N/A
Return on assets
-157.2%
Return on equity
-554.8%
Return on invested capital
-348.5%
Return on capital employed
-472.4%
Return on sales
N/A
Dividend yield
N/A
DPS
N/A
Payout ratio
N/A
ELTX stock price
How has the Elicio Therapeutics stock price performed over time
Intraday
3.91%
1 week
0.21%
1 month
1.27%
1 year
-28.01%
YTD
-42.69%
QTD
-4.97%
Financial performance
How have Elicio Therapeutics's revenue and profit performed over time
Revenue
$0
Gross profit
$0
Operating income
-$41.33M
Net income
-$38.66M
Gross margin
N/A
Net margin
N/A
The operating income has dropped by 51% year-on-year and by 8% since the previous quarter
The net income has declined by 31% year-on-year
Growth
What is Elicio Therapeutics's growth rate over time
Valuation
What is Elicio Therapeutics stock price valuation
P/E
N/A
P/B
N/A
P/S
N/A
EV/EBIT
N/A
EV/EBITDA
N/A
EV/Sales
N/A
Elicio Therapeutics's EPS has soared by 90% YoY and by 22% from the previous quarter
ELTX's equity has dropped by 134% since the previous quarter and by 107% year-on-year
Efficiency
How efficient is Elicio Therapeutics business performance
The company's return on assets has shrunk by 118% YoY and by 21% QoQ
The ROE has plunged by 89% from the previous quarter but it has grown by 47% YoY
ELTX's return on invested capital is down by 41% year-on-year and by 12% since the previous quarter
Dividends
What is ELTX's dividend
DPS
N/A
Dividend yield
N/A
Payout ratio
N/A
There are no recent dividends present for ELTX.
Financial health
How did Elicio Therapeutics financials performed over time
The total assets is 9% smaller than the total liabilities
The quick ratio has shrunk by 82% YoY and by 76% QoQ
The current ratio has plunged by 74% YoY and by 63% from the previous quarter
ELTX's equity has dropped by 134% since the previous quarter and by 107% year-on-year
ELTX's debt is down by 13% YoY and by 3.8% QoQ
All financial data is based on trailing twelve months (TTM) periods - updated quarterly, unless otherwise
specified. Data from 
and Sharadar.